United Kingdom (UK)
Recombinant monoclonal antibody to DLL3. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma SC16.13.
UniProt Accession Number of Target Protein: Q9NYJ7
Alternative Name(s) of Target: Delta-like protein 3; Drosophila Delta homolog 3 (Delta3)
Immunogen: The original antibody was generated by immunizing three strains of mice (Balb/c, CD-1 and FVB) with recombinant human DLL3-Fc or with human DLL3-His fusion constructs.
Specificity: This antibody binds human DLL3 in the EGF2 domain. It does not cross-react with monkey/mouse/rat DLL3. Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Mature human DLL3 consists of a 466 amino acid (aa) extracellular domain (ECD) with one DSL domain and six EGF-like repeats, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain. It is an inhibitory Notch ligand that is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally expressed in normal tissues. It is therefore being explored as a potential therapeutic target in SCLC.
Application Notes: The binding characterization of this antibody to human DLL3 was done using ELISA. Binding affinity of mouse IgG antibody for human DLL3 is 0.3 nM. This antibody can bind human DLL3 expressed on surface of 293 cells via flow cytometry. This antibody can mediate killing of tumor cells expressing DLL3. This antibody was covalently conjugated to PBD cytotoxic agent and the resulting ADCs resulted in tumor growth suppression lasting as long as 20 days. Humanized version is also available and drug conjugations made using the humanized versions also resulted in tumor suppression (US9089615).
Antibody first published in: PMID: